Caffeine and Peptide Interactions With Medications: What Studies Report

Answer first: what the cited literature does and does not cover

Two separate questions are often asked in the same breath: whether collagen peptides interfere with medications, and whether caffeine does. The published record treats them very differently. Caffeine has decades of pharmacology behind it, and a 2015 review in Current Neuropharmacology examined caffeine simultaneously as a cognitive and physical performance enhancer and as a psychoactive drug (PMID 26074744). Oral collagen peptides, by contrast, are not represented by any controlled drug-interaction trial in the verified citation set used for this page, so what follows describes that gap rather than filling it with inference.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, supplement, cosmetic ingredient or research compound. Nothing here describes a protocol, and no quantity is stated unless the cited paper stated it.

Caffeine and medications: what the interaction literature reports

Metabolism is the usual starting point

Most caffeine interaction discussion begins with hepatic metabolism. A 2020 review in Seminars in Fetal & Neonatal Medicine set out the pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns, a population in which hepatic clearance pathways are still maturing and in which caffeine handling therefore differs from adults (PMID 33293242). Researchers studying interactions generally reason from that same metabolic route: anything that alters the enzymes clearing caffeine, or anything cleared by those enzymes alongside caffeine, becomes a candidate interaction.

A psychiatric case report

The most direct interaction document in this citation set is a 2026 report in Bipolar Disorders describing the interaction of fluoxetine and caffeine in a patient with substance-induced mania (PMID 41830474). A single case report is a hypothesis-generating document rather than population evidence, and the study did not establish frequency; it recorded one clinical sequence involving an antidepressant and caffeine together.

Energy drinks as a real-world caffeine vehicle

Because caffeine rarely arrives alone, a 2021 review in Pharmaceutics examined the interaction of energy drinks with prescription medication and with drugs of abuse, treating the beverage rather than the isolated molecule as the exposure of interest (PMID 34683828). That framing matters for any consumer product — including caffeinated collagen or protein drinks — because a formulation contributes sugars, amino acids, herbal extracts and other stimulants alongside caffeine.

Caffeine with other stimulant-like compounds

Not every interaction question involves a prescription drug. A 2017 human study in the Journal of Caffeine Research assessed the drug–drug interaction potential between theacrine and caffeine in humans (PMID 28875060), and a 2016 rat study in Biomolecules & Therapeutics reported a pharmacokinetic interaction of the flavonoid chrysin with caffeine (PMID 27098862). Both illustrate the standard design: give the co-administered compound, then measure what happens to caffeine exposure over time.

Disease states can change the enzymes themselves

Interaction potential is not fixed across individuals. A 2017 study in the Journal of Biochemical and Molecular Toxicology reported in vivo cytochrome P450 activity alterations in mice with diabetic nonalcoholic steatohepatitis (PMID 27712037), a reminder that metabolic disease models have shown shifted drug-metabolising capacity independent of any co-administered drug.

Co-administration in hospital settings

Caffeine citrate is a medication in its own right in neonatology. A 2022 analysis in The Journal of Pediatrics described medication use in the neonatal intensive care unit and changes from 2010 to 2018, mapping which agents were used and how prescribing patterns shifted across that period (PMID 34481808). Read alongside the newborn pharmacokinetics review (PMID 33293242), it shows that caffeine's best-characterised therapeutic context is one where clinicians already manage it as a drug among many.

Effects reported outside the nervous system

Caffeine research is not limited to alertness endpoints. A 2022 study in Life reported that caffeine decreased hepcidin expression and alleviated aberrant iron metabolism under inflammation by regulating the IL-6/STAT3 pathway (PMID 35888113). Findings of that kind are mechanistic and preclinical, and the study did not test them against clinical iron-related therapies in people.

Caffeine as an engineering input

Two papers in this set used caffeine not as a dietary exposure but as a trigger molecule. A 2018 paper in Nature Communications described caffeine-inducible gene switches controlling experimental diabetes (PMID 29921872), and a 2023 paper in iScience reported caffeine-induced release of small molecules from DNA nanostructures (PMID 37250306). Both are relevant to the broader "peptide and caffeine" question because they show researchers deliberately designing protein- and nucleic-acid-based systems that respond to caffeine — an interaction by design rather than by accident.

Membrane-level biophysics

A 2019 study in Colloids and Surfaces B: Biointerfaces took a biophysical approach to how natural compounds interacted with biomembrane models in the context of Alzheimer's disease therapy (PMID 31030024). Model-membrane work of this kind sits several steps upstream of any clinical interaction claim, and researchers reported physical-chemical behaviour rather than outcomes in people.

Study map

Do collagen peptides interfere with medications?

The verified literature summarised on this page contains no clinical or preclinical drug-interaction study of oral collagen peptides. That is a statement about this citation set, not a statement that interactions have been excluded elsewhere; absence of a trial in a given evidence base is not the same as a negative finding, and it is the kind of gap a prescriber or pharmacist is positioned to assess for an individual.

Two practical points do follow from the caffeine literature. First, many collagen products are sold as flavoured powders, gummies or ready-to-drink beverages, and some of those beverages contain caffeine; in that case the caffeine component carries the pharmacology described in the 2015 review of caffeine as a performance enhancer and psychoactive drug (PMID 26074744). Second, the energy-drink review demonstrated that interaction questions about a mixed beverage are addressed at the level of the whole product, because the formulation supplies more than one active constituent (PMID 34683828).

Peptides and caffeine in topical products

A large share of "peptides and caffeine" questions are about cosmetics rather than research peptides. The verified papers here did not evaluate any topical cosmetic formulation, so the sections below describe what the products are, and state plainly where the cited evidence stops.

Hempz age-defying peptide and caffeine body lotions

Hempz body lotions marketed around "age-defying peptides" and caffeine are cosmetic leave-on emulsions in which peptides and caffeine appear as formulation ingredients on the label. No study in this citation set tested such a lotion, measured systemic caffeine absorption from it, or examined it alongside any medication. The caffeine pharmacokinetic work cited here concerned systemic exposure in humans and animals rather than cosmetic skin application (PMID 33293242).

Peptide and caffeine eye patches

Under-eye hydrogel patches frequently list both a peptide blend and caffeine. Again, no controlled interaction study of eye patches appears in the verified set. Researchers assessing caffeine interactions in humans used oral dosing and plasma sampling, as in the theacrine co-administration study (PMID 28875060), which is a different exposure route from a short-contact cosmetic patch.

Peptide and caffeine serums for hair and scalp

Scalp serums combining peptides with caffeine are sold as cosmetic products in most markets. This page's citation set includes no trial of a hair or scalp serum and no measurement of hair or follicle endpoints, so no efficacy or interaction statement can be supported from it. The only caffeine-and-tissue mechanism reported here concerned hepcidin and iron handling in an inflammation model (PMID 35888113).

"Peptides and caffeine" in minimalist skincare lines

Brands such as The Ordinary sell separate peptide-focused and caffeine-focused formulas, and questions about combining them are formulation questions rather than pharmacology questions. Nothing in the verified literature evaluated layering cosmetic actives, and none of the cited caffeine interaction work — including the fluoxetine case report (PMID 41830474) — involved topical products.

Tolerability and adverse events: what studies report

The 2015 review characterised caffeine as a psychoactive drug as well as a performance enhancer, a dual framing that acknowledged its pharmacological activity rather than treating it as an inert dietary component (PMID 26074744). The clearest adverse-event signal in this citation set is the single case report of fluoxetine and caffeine in a patient with substance-induced mania (PMID 41830474), and the energy-drink review considered interactions with prescription medication and drugs of abuse as a category-level concern (PMID 34683828). None of these papers reported on collagen peptides or cosmetic peptide products.

Measurement and handling literacy

Interaction questions often stall on units rather than pharmacology. Milligrams describe the mass of a substance; millilitres describe the volume of a liquid; a percentage on a cosmetic label describes concentration within that formulation, not an amount delivered to the body. Beverages state caffeine content per serving while capsules state it per unit, so two products with identical labels can represent different exposures depending on serving size. Research peptides supplied as lyophilised powder are typically stored cold and protected from light, and product inserts and manufacturer stability documents — not this page — are the source for any specific storage condition. Reading a label accurately is a prerequisite for a pharmacist or physician to answer an interaction question, and the studies cited above illustrate why researchers report exposure in measured, timed terms rather than in servings.

What the cited evidence does not establish

• No paper in this set tested oral collagen peptides against any medication.
• No paper in this set tested a peptide-plus-caffeine lotion, eye patch or serum.
• The fluoxetine finding was a case report, and the study did not estimate how often such an interaction occurs (PMID 41830474).
• Animal and cell findings, including the chrysin pharmacokinetic study in rats (PMID 27098862) and the cytochrome P450 alterations reported in diabetic nonalcoholic steatohepatitis mice (PMID 27712037), were not clinical outcomes in people.
• Caffeine-responsive engineered systems described in Nature Communications (PMID 29921872) and iScience (PMID 37250306) were experimental platforms, not consumer products.

References

• Caffeine: cognitive and physical performance enhancer or psychoactive drug? (Current Neuropharmacology, 2015)
• Caffeine-inducible gene switches controlling experimental diabetes (Nature Communications, 2018)
• Caffeine-induced release of small molecules from DNA nanostructures (iScience, 2023)
• Interaction of Fluoxetine and Caffeine in a Patient With Substance-Induced Mania (Bipolar Disorders, 2026)
• Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns (Seminars in Fetal & Neonatal Medicine, 2020)
• In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice (Journal of Biochemical and Molecular Toxicology, 2017)
• Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018 (The Journal of Pediatrics, 2022)
• Caffeine Decreases Hepcidin Expression to Alleviate Aberrant Iron Metabolism under Inflammation by Regulating the IL-6/STAT3 Pathway (Life, 2022)
• Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans (Journal of Caffeine Research, 2017)
• Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse (Pharmaceutics, 2021)
• Pharmacokinetic Interaction of Chrysin with Caffeine in Rats (Biomolecules & Therapeutics, 2016)
• Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer's disease therapy (Colloids and Surfaces B: Biointerfaces, 2019)